Adverum Biotechnologies (ADVM) Stock Price, News & Analysis

Company Overview

Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is a clinical-stage gene therapy company dedicated to developing next-generation treatments for ocular and rare diseases. Headquartered in Redwood City, California, Adverum leverages its proprietary adeno-associated virus (AAV) platform to deliver potentially one-time, durable therapies that address underlying genetic causes. The company’s research focuses on serious conditions with high unmet medical need, including retinal disorders and hemophilia A.

The company’s pipeline includes ADVM-022, an intravitreal AAV-based gene therapy candidate for the prevention and treatment of neovascular age-related macular degeneration (wet AMD), and ADVM-043, which targets diabetic macular edema. In addition, Adverum is advancing ADVM-269, a systemic AAV vector designed to express factor VIII for patients with severe hemophilia A. Each program is designed to reduce or eliminate the need for repeated hospital visits and chronic treatment regimens.

Originally founded as Avalanche Biotechnologies in 2014 and rebranded as Adverum Biotechnologies in 2015, the company completed its initial public offering on the Nasdaq in 2016. Under the leadership of President and CEO Roy Dunbar and Executive Chairman Glenn Rockman, Adverum has grown its scientific capabilities and manufacturing partnerships, including agreements to secure clinical- and commercial-scale AAV vector production.

Adverum operates with a global perspective, conducting clinical trials across North America and Europe and engaging with regulatory authorities to advance its programs. The company’s mission is to bring transformative gene therapies to patients worldwide, harnessing its expertise in vector design and delivery to develop potentially curative treatments for serious disorders.

Key Stats

• Today's Range: $2.71 to $2.99
• 50-Day Range: $2.05 to $2.97
• 52-Week Range: $1.78 to $9.95
• Volume: 120,119 shs
• Average Volume: 248,802 shs
• Market Capitalization: $57.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.80
• Consensus Rating: Moderate Buy

Adverum Biotechnologies Stock Analysis - MarketRank™

Adverum Biotechnologies scored higher than 88% of companies evaluated by MarketBeat, and ranked 119th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adverum Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Adverum Biotechnologies has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adverum Biotechnologies are expected to decrease in the coming year, from ($4.92) to ($5.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adverum Biotechnologies is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adverum Biotechnologies is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adverum Biotechnologies has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.39% of the float of Adverum Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

Adverum Biotechnologies has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adverum Biotechnologies has recently decreased by 36.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adverum Biotechnologies does not currently pay a dividend.

Dividend Growth

Adverum Biotechnologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.78

Percentage of Shares Shorted

8.39% of the float of Adverum Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

Adverum Biotechnologies has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Adverum Biotechnologies has recently decreased by 36.96%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Adverum Biotechnologies has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Adverum Biotechnologies this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ADVM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Adverum Biotechnologies insiders have bought 472.64% more of their company's stock than they have sold. Specifically, they have bought $149,000.00 in company stock and sold $26,020.00 in company stock.

Percentage Held by Insiders

Only 6.00% of the stock of Adverum Biotechnologies is held by insiders.

Percentage Held by Institutions

48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ADVM Stock Analysis - Frequently Asked Questions

How have ADVM shares performed this year?

Adverum Biotechnologies' stock was trading at $4.67 at the beginning of 2025. Since then, ADVM stock has decreased by 40.7% and is now trading at $2.77.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) announced its quarterly earnings data on Tuesday, April, 15th. The biotechnology company reported ($1.96) EPS for the quarter, missing analysts' consensus estimates of ($1.34) by $0.62.

When did Adverum Biotechnologies' stock split?

Shares of Adverum Biotechnologies reverse split before market open on Thursday, March 21st 2024.The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adverum Biotechnologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 4/15/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADVM
• CIK: 1501756
• Web: www.adverum.com
• Phone: (650) 656-9323
• Fax: 650-329-8151
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Adverum Biotechnologies: $23.80
• High Price Target: $40.00
• Low Price Target: $4.00
• Potential Upside/Downside: +759.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.93 million
• Net Margins: N/A
• Pretax Margin: -15,079.90%
• Return on Equity: -130.53%
• Return on Assets: -66.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.57
• Quick Ratio: 3.57

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 57.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.40 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 20,891,000
• Free Float: 19,638,000
• Market Cap: $57.87 million
• Optionable: Optionable
• Beta: 0.70